David Steiner

TargetGene Biotechnologies LTD

TargetGene is an innovative and agile biotechnology company in it's development stage poised for expansion. TargetGene's R&D is centered around creating efficient and supremely specific DNA editing solutions in living organisms. TargetGene, with it's patented and patent pending "T∙GEE"​ (Genome Editing Engine) platform is the first to invent RNA-guided gene-targeting. TargetGene is aiming to implement the "T∙GEE"​ platform for human gene-therapy with a focus on inherited diseases and cell-based immunotherapy. TargetGene's platforms include In-Vivo assembling nucleases targeted to the cell's genetic material. Highly specific Targeting is achieved through use of the principle of nucleic acid hybridization. Keywords: Genome editing, Gene Targeting, Genome engineering, Nucleases, RNA-guided Genome Engineering (RGEN), Immunotherapy, Cell-based Therapy, Gene Thearapy, Immuno-oncology. Our new laboratories are situated in the Rehovot Science park, Oppenheimer 10, Rehovot, Israel. We are on the lookout for excellent new staff. We encourage experienced professionals skilled in fields relating to gene-therapy cell therapy and protein engineering to apply by email. Contacts and followers welcome.